Live Breaking News & Updates on Rejection Of Favipiravir Patent In Thailand Was Therea Better Way

To print this article, all you need is to be registered or login on Mondaq.com.
On 5 May 2021, the Department of Intellectual Property (DIP) of
Thailand rejected a Thai patent application for a granulated powder
tablet containing 6-fluoro-3-hydroxy-2-pyrazinecarboxamide, also
known as Favipiravir, which is a drug used to treat viral
infections including COVID-19. Favipiravir has been used in many
countries including Thailand to treat COVID-19 patients. 
With the spiking numbers of COVID-19 infections, demand for
Favipiravir has soared with fears of shortage. As Favipiravir can
currently only be imported into the country, Thailand aims to
establish a production hub for the Favipiravir tablets to meet ....

United States , Government Pharmaceutical Organization , Public Health Ministry , Health Organization , Department Of Intellectual Property , Toyama Chemical Co Ltd , Office Action , Intellectual Property , Cooperation Treaty , Rejection Order , Patent Board , Thai Patent , Rejection Of Favipiravir Patent In Thailand Was Therea Better Way , Coronavirus Covid 19 , Operational Impacts And Strategy , Life Sciences , Food And Drugs Law , ஒன்றுபட்டது மாநிலங்களில் , அரசு மருந்து ஆர்கநைஸேஶந் , பொது ஆரோக்கியம் அமைச்சகம் , ஆரோக்கியம் ஆர்கநைஸேஶந் , துறை ஆஃப் அறிவுசார் ப்ராபர்டீ , டோயாமா இரசாயன இணை லிமிடெட் , அலுவலகம் நடவடிக்கை , அறிவுசார் ப்ராபர்டீ , ஒத்துழைப்பு ஒப்பந்தம் ,